# EDGAR Filing Document

**Accession Number:** 0001464165
**File Stem:** 0001477932-23-000362
**Filing Date:** 2023-1
**Character Count:** 5021
**Document Hash:** e1590b1296ae626b6c68bbf7de2e8ed3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001477932-23-000362.hdr.sgml**: 20230118

**ACCESSION NUMBER**: 0001477932-23-000362

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230117

**FILED AS OF DATE**: 20230118

**DATE AS OF CHANGE**: 20230118

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BetterLife Pharma Inc.
- **CENTRAL INDEX KEY:** 0001464165
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 0131

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 333-161157
- **FILM NUMBER:** 23533033

**BUSINESS ADDRESS:**
- **STREET 1:** 1275 WEST 6TH AVENUE
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V6H 1A6
- **BUSINESS PHONE:** 438-884-8841

**MAIL ADDRESS:**
- **STREET 1:** 1275 WEST 6TH AVENUE
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V6H 1A6

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Pivot Pharmaceuticals Inc.
- **DATE OF NAME CHANGE:** 20150417

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Neurokine Pharmaceuticals Inc.
- **DATE OF NAME CHANGE:** 20090514

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16 OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

For the month of January, 2023.

Commission File Number 333-161157

---

| |
|:---|
| **BETTERLIFE PHARMA INC.** |
| (Translation of registrant's name into English) |

---

**1275 WEST 6<sup>TH</sup> AVENUE, #300**

**<u>VANCOUVER, BC V6H 1A6</u>**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

**Note:** Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

**Note:** Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

**Exhibits:**

[99.1](betrf_ex991.htm) [Material Change Report dated January 17, 2023](betrf_ex991.htm)

2<br>

**SIGNATURES**

Pursuant to the requirements of the *Securities Exchange Act of 1934*, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **BETTERLIFE PHARMA INC.** | **BETTERLIFE PHARMA INC.** |
| Date: January 18, 2023 | By: | */s/ Moira Ong* |
|  |  | Name: Moira Ong |
|  |  | Title: Chief Financial Officer |

---

3<br>

## Exhibit 99.1

**EXHIBIT 99.1**

**FORM 51-102F3**

**MATERIAL CHANGE REPORT**

**Item 1 Name and Address of Company**

BetterLife Pharma Inc. (the "Company")

1275 West 6<sup>th</sup> Avenue

Suite 300

Vancouver, British Columbia

V6H 1A6

**Item 2 Date of Material Change**

January 2023 and December 2022

**Item 3 News Releases**

N/A.

**Item 4 Summary of Material Change**

On December 12, 2022, the Company granted 20,000 stock options with exercise price of $0.16 and expiry date of December 11, 2024 to a consultant. On January 13, 2023, the Company granted 1,800,000 stock options with exercise price of $0.16 and expiry date of January 12, 2023 to officers, directors and consultants.

On January 16, 2023, the Company filed a Notice of Meeting and Record Dates for its upcoming Annual General Meeting to be held on March 30, 2023 with a record date of February 10, 2023.

**Item 5 Full Description of Material Change**

Refer to Item 4.

**Item 6 Reliance on subsection 7.1(2) or (3) of National Instrument 51-102**

This Report is not being filed on a confidential basis in reliance on subsection 7.1(2) of National Instrument 51-102.

**Item 7 Omitted Information**

No information has been omitted on the basis that it is confidential information.

**Item 8 Executive Officer**

Further information can be obtained from Ahmad Doroudian, Chief Executive Officer of the Company, at (604) 221-0595.

**Item 9 Date of Report**

January 17, 2023